Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles
Topics & Concepts
AtezolizumabAdjuvantMedicineUrothelial carcinomaOncologyOpen labelCarcinomaInternal medicineUrologyRandomized controlled trialCancerImmunotherapyBladder cancerPembrolizumabBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentUrinary and Genital Oncology Studies